
PRME
Healthcare · Biotechnology · $949.9M market cap
$4.27+0.38 (+9.8%)Nov 13, 4:12 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -3.5% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -0.23 | -0.22 | +4.3% |
| Aug 6, 2026 | Before the open | -0.24 | -0.24 | 0.0% |
| May 7, 2026 | Before the open | -0.25 | -0.28 | -12.0% |
| Mar 3, 2026 | Time not confirmed | -0.26 | -0.24 | +6.9% |
| Nov 7, 2025 | Before the open | -0.25 | -0.32 | -28.0% |
| Aug 7, 2025 | Before the open | -0.36 | -0.41 | -13.9% |
| May 8, 2025 | Before the open | -0.31 | -0.40 | -29.0% |
| Feb 28, 2025 | Time not confirmed | -0.49 | -0.31 | +36.7% |
| Nov 12, 2024 | After the close | -0.42 | -0.44 | -4.8% |
| Aug 8, 2024 | Before the open | -0.39 | -0.46 | -17.9% |
| May 10, 2024 | Before the open | -0.46 | -0.44 | +4.3% |
| Mar 1, 2024 | Before the open | -0.51 | -0.72 | -41.2% |
| Nov 3, 2023 | After the close | -0.46 |
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations…
| -0.55 |
| -19.6% |
| Aug 7, 2023 | After the close | -0.42 | -0.47 | -11.9% |
| May 11, 2023 | Before the open | -0.41 | -0.44 | -7.3% |
| Mar 9, 2023 | Before the open | -0.65 | -0.56 | +13.8% |
| Nov 14, 2022 | After the close | -0.55 | -1.61 | -192.7% |
| May 6, 2022 | Time not confirmed | — | -0.32 | — |
| Dec 20, 2021 | Time not confirmed | — | -0.24 | — |